Clinical Cancer Research Versailles No Abst Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lord, R. V. N.
Right arrow Articles by Rosell, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lord, R. V. N.
Right arrow Articles by Rosell, R.
Clinical Cancer Research Vol. 8, 2286-2291, July 2002
© 2002 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

Low ERCC1 Expression Correlates with Prolonged Survival after Cisplatin plus Gemcitabine Chemotherapy in Non-Small Cell Lung Cancer1

Reginald V. N. Lord2, Jan Brabender2, David Gandara, Vicente Alberola, Carlos Camps, Manuel Domine, Felip Cardenal, José M. Sánchez, Paul H. Gumerlock, Miquel Tarón, José J. Sánchez, Kathleen D. Danenberg, Peter V. Danenberg and Rafael Rosell3

University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California 90033 [R. V. N. L., J. B., P. V. D.]; University of California, Davis Cancer Center, Sacramento, California 95817 [D. G., P. H. G.]; Hospital Arnau de Vilanova, 46015 Valencia, Spain [V. A.]; Hospital General de Valencia, 46014 Valencia, Spain [C.C.]; Fundación Jiménez Diaz, 28005 Madrid, Spain [M. D.]; Institut Català d’Oncologia, 08907 Bellvitge, Barcelona, Spain [F. C.]; Hospital Germans Trias i Pujol, Badalona, s/n 08916 Barcelona, Spain [J. M. S., M. T., R. R.]; Free University of Madrid, 28029 Madrid, Spain [J. J. S.]; and Response Genetics, Los Angeles, California 90033 [K. D. D.]

Purpose: Overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is crucial in the repair of cisplatin (CDDP)-DNA adducts, is reported to negatively influence the effectiveness of CDDP-based therapy for gastric and ovarian cancers. Recent evidence indicates that Gemcitabine (Gem) may modulate ERCC1 nucleotide excision repair activity, and down-regulation of DNA repair activity by ERCC1 antisense RNA reportedly inhibits synergism of CDDP/Gem. We investigated whether ERCC1 mRNA expression levels were associated with clinical outcomes after treatment with a combination Gem/CDDP regimen for patients with advanced stage non-small cell lung cancer (NSCLC).

Experimental Design: Response and survival were correlated with the level of ERCC1 expression in 56 patients with advanced (stage IIIb or IV) NSCLC treated as part of a multicenter randomized trial with Gem 1250 mg/m2 days 1 and 8 plus CDDP 100 mg/m2 on day 1 every 3 weeks. mRNA was isolated from paraffin-embedded pretreatment primary tumor specimens, and relative expression levels of ERCC1/ß-actin were measured using a quantitative reverse transcription-PCR (Taqman) system.

Results: ERCC1 expression was detectable in all tumors. There were no significant differences in ERCC1 levels by gender, age, performance status, weight loss, or tumor stage. The overall response rate was 44.7%. There were no significant associations between ERCC1 expression and response. Median overall survival was significantly longer in patients with low ERCC1 expression tumors (61.6 weeks; 95% confidence interval, 42.4–80.7 weeks) compared to patients with high expression tumors (20.4 weeks, 95% confidence interval, 6.9–33.9 weeks). ERCC1 expression, Eastern Cooperative Oncology Group performance status, and presence of weight loss were significant prognostic factors for survival in a Cox proportional hazards multivariable analysis.

Conclusions: These data suggest that ERCC1 expression is a predictive factor for survival after CDDP/Gem therapy in advanced NSCLC. Although there was a trend toward decreased response with high ERCC1 mRNA levels, this difference failed to reach statistical significance. This result may reflect the impact of Gem and the requirement for ERCC1 expression for CDDP/Gem synergism or may be attributable to the relatively small patient sample size in this study. Prospective studies of ERCC1 as a predictive marker for activity of CDDP-based regimens in NSCLC are warranted.




This article has been cited by other articles:


Home page
 INT J SURG PATHOLHome page
G. Rossi, G. Pelosi, P. Graziano, M. Barbareschi, and M. Papotti
Review Article: A Reevaluation of the Clinical Significance of Histological Subtyping of Non--Small-Cell Lung Carcinoma: Diagnostic Algorithms in the Era of Personalized Treatments
International Journal of Surgical Pathology, June 1, 2009; 17(3): 206 - 218.
[Abstract] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
L. J. Inge, K. D. Coon, M. A. Smith, and R. M. Bremner
Expression of LKB1 tumor suppressor in non-small cell lung cancer determines sensitivity to 2-deoxyglucose.
J. Thorac. Cardiovasc. Surg., March 1, 2009; 137(3): 580 - 586.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H.-T. Kim, J.-E. Lee, E.-S. Shin, Y.-K. Yoo, J.-H. Cho, M.-H. Yun, Y.-H. Kim, S.-K. Kim, H.-J. Kim, T.-W. Jang, et al.
Effect of BRCA1 Haplotype on Survival of Non-Small-Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy
J. Clin. Oncol., December 20, 2008; 26(36): 5972 - 5979.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Besse and T. Le Chevalier
Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer: A Fading Effect?
J. Clin. Oncol., November 1, 2008; 26(31): 5014 - 5017.
[Full Text] [PDF]

Home page
 JCOHome page
T. C. Krivak, K. M. Darcy, C. Tian, D. Armstrong, B. E. Baysal, H. Gallion, C. B. Ambrosone, and J. A. DeLoia
Relationship Between ERCC1 Polymorphisms, Disease Progression, and Survival in the Gynecologic Oncology Group Phase III Trial of Intraperitoneal Versus Intravenous Cisplatin and Paclitaxel for Stage III Epithelial Ovarian Cancer
J. Clin. Oncol., July 20, 2008; 26(21): 3598 - 3606.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. K. Kim, K.-J. Cho, G. Y. Kwon, S.-I. Park, Y. H. Kim, J. H. Kim, H.-Y. Song, J. H. Shin, H. Y. Jung, G. H. Lee, et al.
Patients with ERCC1-Negative Locally Advanced Esophageal Cancers May Benefit from Preoperative Chemoradiotherapy
Clin. Cancer Res., July 1, 2008; 14(13): 4225 - 4231.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Yu, X. Zhang, J. Liu, P. Yuan, W. Tan, Y. Guo, T. Sun, D. Zhao, M. Yang, J. Liu, et al.
Characterization of Functional Excision Repair Cross-Complementation Group 1 Variants and Their Association with Lung Cancer Risk and Prognosis
Clin. Cancer Res., May 1, 2008; 14(9): 2878 - 2886.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. P. Martin, T. C. Hamilton, and R. J. Schilder
Platinum Resistance: The Role of DNA Repair Pathways
Clin. Cancer Res., March 1, 2008; 14(5): 1291 - 1295.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
G. Bepler
Genes Predictive of Chemotherapeutic Efficacy in Non-small Cell Lung Cancer
ASCO Educational Book, January 1, 2008; 2008(1): 350 - 352.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Smith, D. Su, I. A. Rigault de la Longrais, P. Schwartz, M. Puopolo, T. J. Rutherford, G. Mor, H. Yu, and D. Katsaros
ERCC1 Genotype and Phenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum-Based Therapy
J. Clin. Oncol., November 20, 2007; 25(33): 5172 - 5179.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J.-C. Soria
ERCC1-Tailored Chemotherapy in Lung Cancer: The First Prospective Randomized Trial
J. Clin. Oncol., July 1, 2007; 25(19): 2648 - 2649.
[Full Text] [PDF]

Home page
 JCOHome page
G. Simon, A. Sharma, X. Li, T. Hazelton, F. Walsh, C. Williams, A. Chiappori, E. Haura, T. Tanvetyanon, S. Antonia, et al.
Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy in Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., July 1, 2007; 25(19): 2741 - 2746.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Cobo, D. Isla, B. Massuti, A. Montes, J. M. Sanchez, M. Provencio, N. Vinolas, L. Paz-Ares, G. Lopez-Vivanco, M. A. Munoz, et al.
Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non-Small-Cell Lung Cancer
J. Clin. Oncol., July 1, 2007; 25(19): 2747 - 2754.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Handra-Luca, J. Hernandez, G. Mountzios, E. Taranchon, J. Lacau-St-Guily, J.-C. Soria, and P. Fouret
Excision Repair Cross Complementation Group 1 Immunohistochemical Expression Predicts Objective Response and Cancer-Specific Survival in Patients Treated by Cisplatin-Based Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
Clin. Cancer Res., July 1, 2007; 13(13): 3855 - 3859.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. F. Giachino, P. Ghio, S. Regazzoni, G. Mandrile, S. Novello, G. Selvaggi, D. Gregori, M. DeMarchi, and G. V. Scagliotti
Prospective Assessment of XPD Lys751Gln and XRCC1 Arg399Gln Single Nucleotide Polymorphisms in Lung Cancer
Clin. Cancer Res., May 15, 2007; 13(10): 2876 - 2881.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. M. Darcy, C. Tian, and E. Reed
A Gynecologic Oncology Group Study of Platinum-DNA Adducts and Excision Repair Cross-Complementation Group 1 Expression in Optimal, Stage III Epithelial Ovarian Cancer Treated with Platinum-Taxane Chemotherapy
Cancer Res., May 1, 2007; 67(9): 4474 - 4481.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H-C Kwon, M. Roh, S. Oh, S-H Kim, M. Kim, J-S Kim, and H-J Kim
Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer
Ann. Onc., March 1, 2007; 18(3): 504 - 509.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J Bellmunt, L Paz-Ares, M Cuello, F. Cecere, S Albiol, V Guillem, E Gallardo, J Carles, P Mendez, J. de la Cruz, et al.
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy
Ann. Onc., March 1, 2007; 18(3): 522 - 528.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P Ceppi, M Volante, S Novello, I Rapa, K. Danenberg, P. Danenberg, A Cambieri, G Selvaggi, S Saviozzi, R Calogero, et al.
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine
Ann. Onc., December 1, 2006; 17(12): 1818 - 1825.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Bepler, I. Kusmartseva, S. Sharma, A. Gautam, A. Cantor, A. Sharma, and G. Simon
RRM1 Modulated In Vitro and In Vivo Efficacy of Gemcitabine and Platinum in Non-Small-Cell Lung Cancer
J. Clin. Oncol., October 10, 2006; 24(29): 4731 - 4737.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
K. A. Olaussen, A. Dunant, P. Fouret, E. Brambilla, F. Andre, V. Haddad, E. Taranchon, M. Filipits, R. Pirker, H. H. Popper, et al.
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
N. Engl. J. Med., September 7, 2006; 355(10): 983 - 991.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
E. Giovannetti, V. Mey, S. Nannizzi, G. Pasqualetti, M. Del Tacca, and R. Danesi
Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer.
Mol. Cancer Ther., June 1, 2006; 5(6): 1387 - 1395.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Giovannetti, M. Del Tacca, V. Mey, N. Funel, S. Nannizzi, S. Ricci, C. Orlandini, U. Boggi, D. Campani, M. Del Chiaro, et al.
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
Cancer Res., April 1, 2006; 66(7): 3928 - 3935.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Suzuki, Y. Daigo, N. Ishikawa, T. Kato, S. Hayama, T. Ito, E. Tsuchiya, and Y. Nakamura
ANLN Plays a Critical Role in Human Lung Carcinogenesis through the Activation of RHOA and by Involvement in the Phosphoinositide 3-Kinase/AKT Pathway
Cancer Res., December 15, 2005; 65(24): 11314 - 11325.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
L. Thomas, L. A. Doyle, and M. J. Edelman
Lung Cancer in Women: Emerging Differences in Epidemiology, Biology, and Therapy
Chest, July 1, 2005; 128(1): 370 - 381.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Y. Chang, R. Komaki, R. Sasaki, Z. Liao, C. W. Stevens, C. Lu, F. V. Fossella, P. K. Allen, J. D. Cox, M. R. Spitz, et al.
High Mutagen Sensitivity in Peripheral Blood Lymphocytes Predicts Poor Overall and Disease-Specific Survival in Patients with Stage III Non-Small Cell Lung Cancer Treated with Radiotherapy and Chemotherapy
Clin. Cancer Res., April 15, 2005; 11(8): 2894 - 2898.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K.-S. Kim, J.-Y. Jeong, Y.-C. Kim, K.-J. Na, Y.-H. Kim, S.-J. Ahn, S.-M. Baek, C.-S. Park, C.-M. Park, Y.-I. Kim, et al.
Predictors of the Response to Gefitinib in Refractory Non-Small Cell Lung Cancer
Clin. Cancer Res., March 15, 2005; 11(6): 2244 - 2251.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. R. Simon, S. Sharma, A. Cantor, P. Smith, and G. Bepler
ERCC1 Expression Is a Predictor of Survival in Resected Patients With Non-small Cell Lung Cancer
Chest, March 1, 2005; 127(3): 978 - 983.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Suk, S. Gurubhagavatula, S. Park, W. Zhou, L. Su, T. J. Lynch, J. C. Wain, D. Neuberg, G. Liu, and D. C. Christiani
Polymorphisms in ERCC1 and Grade 3 or 4 Toxicity in Non-Small Cell Lung Cancer Patients
Clin. Cancer Res., February 15, 2005; 11(4): 1534 - 1538.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
M. Taron, R. Rosell, E. Felip, P. Mendez, J. Souglakos, M. S. Ronco, C. Queralt, J. Majo, J. M. Sanchez, J. J. Sanchez, et al.
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer
Hum. Mol. Genet., October 1, 2004; 13(20): 2443 - 2449.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Isla, C. Sarries, R. Rosell, G. Alonso, M. Domine, M. Taron, G. Lopez-Vivanco, C. Camps, M. Botia, L. Nunez, et al.
Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer
Ann. Onc., August 1, 2004; 15(8): 1194 - 1203.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Zhou, S. Gurubhagavatula, G. Liu, S. Park, D. S. Neuberg, J. C. Wain, T. J. Lynch, L. Su, and D. C. Christiani
Excision Repair Cross-Complementation Group 1 Polymorphism Predicts Overall Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy
Clin. Cancer Res., August 1, 2004; 10(15): 4939 - 4943.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C.-K. Youn, M.-H. Kim, H.-J. Cho, H.-B. Kim, I.-Y. Chang, M.-H. Chung, and H. J. You
Oncogenic H-Ras Up-Regulates Expression of ERCC1 to Protect Cells from Platinum-Based Anticancer Agents
Cancer Res., July 15, 2004; 64(14): 4849 - 4857.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Rosell, E. Felip, M. Taron, J. Majo, P. Mendez, M. Sanchez-Ronco, C. Queralt, J. J. Sanchez, and J. Maestre
Gene Expression as a Predictive Marker of Outcome in Stage IIB-IIIA-IIIB Non-Small Cell Lung Cancer After Induction Gemcitabine-Based Chemotherapy Followed By Resectional Surgery
Clin. Cancer Res., June 15, 2004; 10(12): 4215S - 4219S.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. I. Wu, J. A. Brown, M. J. Dorie, L. Lazzeroni, and J. M. Brown
Genome-Wide Identification of Genes Conferring Resistance to the Anticancer Agents Cisplatin, Oxaliplatin, and Mitomycin C
Cancer Res., June 1, 2004; 64(11): 3940 - 3948.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
U. Warnecke-Eberz, R. Metzger, F. Miyazono, S. E. Baldus, S. Neiss, J. Brabender, H. Schaefer, W. Doerfler, E. Bollschweiler, H. P. Dienes, et al.
High Specificity of Quantitative Excision Repair Cross-Complementing 1 Messenger RNA Expression for Prediction of Minor Histopathological Response to Neoadjuvant Radiochemotherapy in Esophageal Cancer
Clin. Cancer Res., June 1, 2004; 10(11): 3794 - 3799.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Rosell, K. D. Danenberg, V. Alberola, G. Bepler, J. J. Sanchez, C. Camps, M. Provencio, D. Isla, M. Taron, P. Diz, et al.
Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients
Clin. Cancer Res., February 15, 2004; 10(4): 1318 - 1325.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. A. Moufarij, D. R. Phillips, and C. Cullinane
Gemcitabine Potentiates Cisplatin Cytotoxicity and Inhibits Repair of Cisplatin-DNA Damage in Ovarian Cancer Cell Lines
Mol. Pharmacol., April 1, 2003; 63(4): 862 - 869.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Selvakumaran, D. A. Pisarcik, R. Bao, A. T. Yeung, and T. C. Hamilton
Enhanced Cisplatin Cytotoxicity by Disturbing the Nucleotide Excision Repair Pathway in Ovarian Cancer Cell Lines
Cancer Res., March 15, 2003; 63(6): 1311 - 1316.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
R. Danesi, F. De Braud, S. Fogli, T. M. De Pas, A. Di Paolo, G. Curigliano, and M. Del Tacca
Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer
Pharmacol. Rev., March 1, 2003; 55(1): 57 - 103.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Galani, P. A. Ellis, and P. G. Harper
Small-Cell Lung Cancer, High Growth Rate, High Response Rate to Chemotherapy: Ideal for High-Dose Chemotherapy?
J. Clin. Oncol., October 1, 2002; 20(19): 3941 - 3943.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.